BioCardia Clears Key Hurdle for CardiAMP Cell Therapy Approval in Japan
Event summary
- BioCardia received a favorable Consultation Record from Japan’s PMDA supporting regulatory submission for CardiAMP cell therapy in ischemic heart failure.
- PMDA estimates 20,000 Japanese patients could initially be eligible for the therapy.
- BioCardia plans to submit for approval within seven months, targeting commercialization post-MHLW certification.
- The therapy has FDA Breakthrough designation and is reimbursed by CMS in the U.S.
The big picture
BioCardia’s progress in Japan underscores the growing global interest in cell-based therapies for heart failure, a market with significant unmet needs. The PMDA’s support validates CardiAMP’s clinical profile, positioning BioCardia to compete in Japan’s $300M+ ischemic heart failure market. Success here could set a precedent for regulatory approvals in other high-value territories.
What we're watching
- Regulatory Execution
- Whether BioCardia can address PMDA’s remaining data requests and secure approval within the seven-month submission timeline.
- Market Access
- The pace at which BioCardia establishes proper-use guidelines and post-market surveillance infrastructure in Japan.
- Commercialization Strategy
- How BioCardia leverages its Designated Marketing Authorization Holder pathway to accelerate CardiAMP’s launch in Japan.
Related topics